Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 6 | 5 |
| List of Tables | 9 | 1 |
| List of Figures | 10 | 1 |
| Introduction | 11 | 8 |
| Cancer Epidemiology | 11 | 1 |
| Disease Initiation and Propagation | 11 | 1 |
| Symptoms | 12 | 1 |
| Symptoms of Lung Cancer | 12 | 1 |
| Symptoms of Prostate Cancer | 12 | 1 |
| Symptoms of Colorectal Cancer | 12 | 1 |
| Symptoms of Breast Cancer | 12 | 1 |
| Symptoms of Melanoma | 12 | 1 |
| Symptoms of Stomach Cancer | 12 | 1 |
| Current Treatment and Management | 13 | 1 |
| Active Surveillance or the Wait-and See Approach | 13 | 1 |
| Surgery | 13 | 1 |
| Radiation Therapy | 13 | 1 |
| Chemotherapy | 13 | 1 |
| Targeted Therapy | 13 | 1 |
| Hormone Therapy | 14 | 1 |
| Immunotherapy | 14 | 1 |
| Virally Induced Cancers and Prophylactic Vaccines | 14 | 1 |
| Cancer, the Immune system and Therapeutic Vaccines | 15 | 1 |
| Mechanisms of Immune System Evasion | 15 | 1 |
| Mechanisms of Immune System Disabling | 15 | 1 |
| Why Develop Therapeutic Cancer Vaccines? | 16 | 1 |
| Types of Therapeutic Cancer Vaccine | 16 | 1 |
| Anti-Idiotype Vaccines | 16 | 1 |
| Whole-Cell-Derived Vaccines | 16 | 1 |
| Cellular Immunotherapy | 17 | 1 |
| Antigen-Based Vaccines | 17 | 1 |
| DNA-Based Vaccines | 17 | 1 |
| Vector-Based (Microorganism-Facilitated) Vaccines | 17 | 1 |
| Oncolytic Virus Vaccines | 18 | 1 |
| Adjuvants | 18 | 1 |
| Marketed Products | 19 | 5 |
| Provenge an Autologous Cellular Immunotherapy Vaccine for the Treatment of Hormone-Refractory Prostate Cancer | 19 | 1 |
| Overview | 19 | 1 |
| Mechanism of Action and Molecular Target | 19 | 1 |
| Formulation and Dosing | 19 | 1 |
| Provenge within the Clinical Landscape for Prostate Cancer | 19 | 1 |
| Company Profile and Patent Expiry | 20 | 1 |
| Recent Sales and Commercialization of Provenge | 20 | 2 |
| Current and Future Market Competitors for Provenge | 22 | 2 |
| Product Pipeline | 24 | 28 |
| Pipeline Overview | 24 | 3 |
| Developmental Pipeline of all Major Indications | 27 | 1 |
| Lung Cancer | 27 | 2 |
| Breast Cancer | 29 | 2 |
| Colorectal Cancer | 31 | 1 |
| Stomach Cancer | 32 | 1 |
| Prostate Cancer | 33 | 2 |
| Melanoma | 35 | 1 |
| Clinical Trials | 36 | 1 |
| Clinical Trial Duration | 36 | 2 |
| Clinical Trial Size | 38 | 1 |
| Clinical Trial Endpoints | 39 | 2 |
| Clinical Trial Failure | 41 | 1 |
| Clinical Trial Failure Rates | 41 | 1 |
| Failure Rates by Vaccine Type | 42 | 1 |
| Reasons for Clinical Trial Failure | 43 | 1 |
| Key Companies Developing Cancer Vaccines | 44 | 1 |
| Promising Drugs in the Developmental Pipeline | 45 | 1 |
| Drug: Allovectin | 45 | 1 |
| Drug: Lucanix (belagenpumatucel-L) | 46 | 1 |
| Drug: BiovaxID | 46 | 1 |
| Drug: DCVax L | 47 | 1 |
| Drug: DCVax-Prostate | 47 | 1 |
| Drug: MAGE-A3 Antigen-Specific Cancer Immunotherapeutic | 48 | 1 |
| Drug: GV-1001 | 48 | 1 |
| Drug: Hyperacute Pancreas Immunotherapy | 49 | 1 |
| Drug: NeuVax (nelipepimut-s) | 49 | 1 |
| Drug: OncoVax | 49 | 1 |
| Drug: Prostvac (rilimogene galvacirepvec) | 50 | 1 |
| Drug: Stimuvax (emepepimut-S) | 50 | 1 |
| Drug: OncoVex (talimogene laherparepvec) | 51 | 1 |
| Forecasting | 52 | 33 |
| Therapeutic Cancer Vaccines Market to 2019 Global | 52 | 1 |
| Treatment Usage Patterns | 53 | 1 |
| Annual Cost of Treatment | 53 | 1 |
| Colorectal Cancer | 53 | 1 |
| Emerging Cancer Vaccines and Anticipated Treatment Usage Patterns | 53 | 1 |
| Annual Cost of Therapy | 54 | 2 |
| Market Size | 56 | 2 |
| Glioblastoma Multiforme | 58 | 1 |
| Emerging Cancer Vaccines and their Treatment Usage Patterns | 58 | 1 |
| Annual Cost of Therapy | 59 | 1 |
| Market Size | 60 | 2 |
| Lymphoma | 62 | 1 |
| Emerging Cancer Vaccines for Lymphoma and their Treatment Usage Patterns | 62 | 1 |
| Annual Cost of Therapy | 62 | 2 |
| Market Revenues | 64 | 2 |
| Melanoma | 66 | 1 |
| Emerging Cancer Vaccines and Anticipated Treatment Usage Patterns | 66 | 1 |
| Annual Cost of Therapy | 67 | 2 |
| Market Size | 69 | 2 |
| Non-Small-Cell Lung Cancer | 71 | 1 |
| Emerging Vaccines and Treatment Usage Patterns | 71 | 1 |
| Annual Cost of Therapy | 71 | 2 |
| Market Size | 73 | 1 |
| Pancreatic Cancer | 74 | 1 |
| Emerging Cancer Vaccines and their Market Impact | 74 | 1 |
| Annual Cost of Therapy | 74 | 2 |
| Market Revenues | 76 | 2 |
| Prostate Cancer | 78 | 1 |
| Treatment Usage Patterns and the Impact of Emerging Vaccines | 78 | 1 |
| Annual Cost of Treatment | 78 | 2 |
| Market Revenues | 80 | 2 |
| Drivers and Barriers for Therapeutic Cancer Vaccines Market | 82 | 1 |
| Drivers | 82 | 1 |
| Patient Desire for Safer and More Effective Treatment | 82 | 1 |
| Patient Desire for Extension of Life | 82 | 1 |
| High Cost of Treatment Set to Increase | 82 | 1 |
| Sustained Innovation in the Developmental Pipeline | 83 | 1 |
| Barriers | 83 | 1 |
| Issues with Clinical Trial Design | 83 | 1 |
| Disease Stage and Patient Selection | 83 | 1 |
| Small Companies may Fail to Secure Funding | 83 | 1 |
| Manufacturing and Logistics | 83 | 1 |
| Pricing and Reimbursement | 84 | 1 |
| Appendix | 85 | 31 |
| Provenge Clinical Trial Titles (Table 3) | 85 | 1 |
| Predicated Annual Cost of Therapy | 85 | 4 |
| Colon Cancer | 85 | 1 |
| Glioblastoma Multiforme | 85 | 1 |
| Lymphoma | 86 | 1 |
| Melanoma | 86 | 1 |
| Non-Small-Cell Lung Cancer | 87 | 1 |
| Pancreatic Cancer | 87 | 1 |
| Prostate Cancer | 88 | 1 |
| Predicted Market Forecasts | 88 | 4 |
| Colon Cancer | 88 | 1 |
| Glioblastoma Multiforme | 89 | 1 |
| Lymphoma | 89 | 1 |
| Melanoma | 90 | 1 |
| Non-Small-Cell Lung Cancer | 90 | 1 |
| Pancreatic Cancer | 91 | 1 |
| Prostate | 91 | 1 |
| All Pipeline Drugs by Phase | 92 | 14 |
| Discovery | 92 | 1 |
| Preclinical | 93 | 2 |
| IND-Filed and Phase 0 | 95 | 1 |
| Phase I | 96 | 5 |
| Phase II | 101 | 4 |
| Phase III | 105 | 1 |
| Market Definitions | 106 | 1 |
| Abbreviations | 107 | 1 |
| Sources | 108 | 3 |
| Research Methodology | 111 | 3 |
| Coverage | 111 | 1 |
| Secondary Research | 111 | 1 |
| Primary Research | 112 | 1 |
| Therapeutic Landscape | 112 | 1 |
| Epidemiology-Based Forecasting | 112 | 1 |
| Analogous Forecasting Methodology | 113 | 1 |
| Diseased Population | 113 | 1 |
| Prescription Population | 113 | 1 |
| Market Size by Geography | 114 | 1 |
| Forecasting Model for Therapeutic Areas | 114 | 1 |
| Geographical Landscape | 115 | 1 |
| Pipeline Analysis | 115 | 1 |
| Expert Panel Validation | 115 | 1 |
| Contact Us | 115 | 1 |
| Disclaimer | 115 | 1 |